AstraZeneca, Amgen tout PhIII win for 'breakthrough' asthma drug, checking a blockbuster box that Dupixent didn't
A closely watched “breakthrough” asthma drug has hit all the right notes in a Phase III, AstraZeneca and Amgen say, paving the way to reach a currently untapped patient population.
We’re not getting much beyond the announcement that tezepelumab met the primary endpoint, but execs’ enthusiastic comments suggest that what they’re seeing backs up the “unprecedented” results that cemented their FDA breakthrough designation.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.